{"entity":{"id":"nct04322617","kind":"trial","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","aka":["ATHENA"],"tldr":"A phase 2/3 trial of anlotinib in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.","summary":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer is a phase 2/3, interventional study registered as NCT04322617 by Hunan Province Tumor Hospital, with a registry enrolment figure of 1200 participants, started 2020-03-24 and due to reach its primary completion in 2028-03-24. Interventions recorded: Anlotinib plus the same Immune Checkpoint Inhibitors.; Anlotinib plus the new Immune Checkpoint Inhibitors.; Anlotinib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Progression free survival time (PFS). Lung eligibility wording from the registry: \"Histopathology or cytology confirmed lung cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04322617","url":"https://clinicaltrials.gov/study/NCT04322617"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["anlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04322617","phase":"2/3","setting":"Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer","sponsor":"Hunan Province Tumor Hospital","participation":[{"nct":"NCT04322617","source":"https://clinicaltrials.gov/study/NCT04322617","fetchedAt":"2026-10-07T16:53:18.074Z","studySha256":"beda2fc3e41634100021c154cb2e0e461ea859b7329bed82f1223cb70edcc58a","overallStatus":"RECRUITING","lastUpdatePosted":"2024-06-04","leadSponsor":"Hunan Province Tumor Hospital","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1200,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2020-03-24","startedType":"actual","enrolled":1200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04322617/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}